PDC*line Pharma

Eric Halioua, CEO

April 21 | 9:45am | Gaudi 2 Ballroom

Liege, Belgium


In-Person Presentation

PDC*line Pharma is a clinical-stage spin-off of the French Blood Bank that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of plasmacytoid dendritic cells. Based on a robust preclinical package and a first-in-human Phase Ib in melanoma, PDC*line Pharma has initiated clinical development in lung cancer with a new candidate and neoantigens. PDC*line Pharma comprises a team of 27 people based in Belgium and France. The company has raised nearly €52M. The last rounds have been led by the Asian VC firm Korean Investment Partners. In March 2019, the company granted an exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences for the development and commercialization of PDC*lung, a vaccine for lung cancer. The total deal value is $123M plus significant tiered royalties on net sales in Asia.


By using this website you agree to accept our Privacy Policy and Terms & Conditions